ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Latest Advances in the Development of CDK4/6 Inhibitors in HR+ Breast Cancer

Richard S. Finn, MD
Published Online:4:40 PM, Mon November 27, 2017

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses advances in the development of CDK4/6 inhibitors for the treatment of hormone receptor (HR)-positive breast cancer.    
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.